comparemela.com

Page 2 - Exeltis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Luye Pharma Group: Luye Pharma Grants Exeltis Exclusive Commercialization Rights to Its Innovative Alzheimer s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Poland

BASEL, Switzerland, March 31, 2022 /PRNewswire/ Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma

Luye pharmaExeltis pharmaInsud pharmaBruno delieExeltis pharmaceuticals holdingLuye pharma groupPrnewswire luye pharma groupWomen healthAlzheimer disease internationalAlzheimer associationInsud pharma groupPharma groupLuye pharma switzerlandRivastigmine multi day transdermal patchGeneral managerCentral nervous system

Lupin in promotional agreement with Exeltis for SOLOSEC

SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women and Trichomoniasis in adults

Vinita guptaWomen healthLupin pharmaceuticalsExeltis united statesBacterial vaginosisHealthcare providers

Lupin inks pact with Exeltis to promote Solosec drug in US

Lupin inks pact with Exeltis to promote Solosec drug in US

Vinita guptaExeltis inc

EIB signs €15 million deal with Dutch med-tech company Xeltis in Netherlands

Xeltis’ so-called endogenous tissue restoration (ETR) uses the patient’s natural healing system to restore heart valves and blood vessels with the patient’s own tissue.

Kris peetersEliane schutteEuropean guarantee fundEuropean investment bankPresident krisKris peetersEuropean investment bankEliane schutte

vimarsana © 2020. All Rights Reserved.